Page 58 - 79_02

C.
Martín
y
A.
I.
Torres

27. Luo,
Q.;,
Gu,
Y.;
Zheng,
W.
et
al.
(2011)
Erlotinib
inhibits
T-­-cell-­-mediated
immune
response

via
down-­-regulation
of
the
c-­-Raf/ERK
cascade
and
Akt
signaling
pathway.
Toxicol
Appl

Pharmacol
251,
130-­-136.

28. Duffour,
J.;
The´zenas,
S.;
Dereure,
O.
et
al.
(2010)
Inter-­-observer
agreement
between

dermatologists
and
oncologists
in
assessing
dermatological
toxicities
in
patients
with

metastatic
colorectal
cancer
treated
by
cetuximab-­-based
chemotherapies:
A
pilot

comparative
study.
Eur
J
Cancer
46,
3169-­-3174.

29. Dinh,
P.;
Harnett,
P.;
Piccart-­-Gebhart,
MJ.;
Awada,
A.
(2008)
New
therapies
for
ovarian

cancer:
Cytotoxics
and
molecularly
targeted
agents.
Crit
Rev
Oncol/hematol;
67:103-­-112.

30. Seiden
MV,
Burris
HA,
Matulonis
U,
et
al.
A
phase
II
trial
of
EMD72000
(matuzumab),
a

humanized
anti-­-EGFR
monoclonal
antibody,
in
patients
with
platinum-­-resistant
ovarian

and
primary
peritoneal
malignancies.
Gynecol
Oncol
104,
727-­-731
(2007).

31. Ismael.
GF.;
Dornelles.
D.;
Mano,
MS.;
Awada.
A.
(2008)Novel
cytotoxic
drugs:
Old

challenges,
new
solutions.
Cancer
Treat
Rev
34,
81-­-91.

32. Hotta,
K.;
Ueok,
H.
(2005)
New
cytotoxic
agents:
a
review
of
the
literature.
Crit
Rev

Oncol/hematol
55,
45-­-65.

33. Natsume,
T.;
Watanabe,
J.;
Koh,
Y.
et
al.
(2003)
Antitumor
activity
of
TZT-­-1027

(soblidotin)
against
vascular
endothelial
growth
factor
secreting
human
lung
cancer
in

vivo.
Cancer
Sci
94,
826-­-833.

34. Natsume
T,
Watanabe
J,
Koh
Y,
et
al.
(2003)
Antitumor
activity
of
TZT-­-1027
(Soblidotin)

against
vascular
endothelial
growth
factor-­-secreting
human
lung
cancer
in
vivo.
Cancer

Sci
94,
826-­-
833.

35. Riely,
GJ.;
Gadgeel,
S.;
Rothman,
I.;
Saidman,
B.;
Sabbath,
K.;
Feit,
K.
(2007)
A
phase
2
study

of
TZT-­-1027,
administered
weekly
to
patients
with
advanced
non-­-small
cell
lung
cancer

following
treatment
with
platinum-­-based
chemotherapy.
Lung
Cancer
55,
181-­-185.

36. Kamsteeg,
M.;
Rutherford,
T.;
Sapi,
E.;
et
al.
(2003)
Phenoxodiol
–an
isoflavone
analog–

induces
apoptosis
in
chemoresistant
ovarian
cancer
cells.
Oncogene
22(17),
2611-­-2620.

37. Aguero,
MF.;
Facchinetti,
MM.;
Sheleg,
Z.;
Senderowicz,
AM.
(2005)
Phenoxodiol,
a
novel

isoflavone,
induces
G1
arrest
by
specific
loss
in
cyclin-­-dependent
kinase
2
activity
by
p53-­-

independent
induction
of
p21WAF1/CIP1.
Cancer
Res
65(8),
3364-­-3373.

38. Tonary,
AM.;
Macdonald,
EA.;
Faught,
W.
et
al.
(2000)
Lack
of
expression
of
c-­-Kit
in

ovarian
cancers
is
associated
with
poor
prognosis.
Int
J
Cancer
89(3),
242-­-250.

39. Reynoso,
D.;
Nolden,
LK.;
Yang,
D.;
et
al.
(2011)
Synergistic
induction
of
apoptosis
by
the

Bcl-­-2
inhibitor
ABT-­-737
and
imatinib
mesylate
in
gastrointestinal
stromal
tumor
cells.

Mol
Oncol
5,
93-­-104.

228